Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Intangibles (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Intangibles for 5 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 12.9% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 million through Dec 2025, down 12.9% year-over-year, with the annual reading at $4.8 million for FY2025, N/A changed from the prior year.
  • Intangibles for Q4 2025 was $4.5 million at Neuphoria Therapeutics, down from $4.6 million in the prior quarter.
  • The five-year high for Intangibles was $7.0 million in Q2 2022, with the low at $4.5 million in Q4 2025.
  • Average Intangibles over 4 years is $5.3 million, with a median of $5.1 million recorded in 2024.
  • Peak annual rise in Intangibles hit 12.5% in 2025, while the deepest fall reached 12.9% in 2025.
  • Over 4 years, Intangibles stood at $7.0 million in 2022, then dropped by 12.72% to $6.2 million in 2023, then dropped by 16.49% to $5.1 million in 2024, then fell by 12.9% to $4.5 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $4.5 million, $4.6 million, and $4.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.